TAG:
genetic test
Market Changes Lead LabCorp To Follow New Strategic Direction
By Robert Michel | From the Volume VIII No. 4 – March 19, 2001 Issue
CEO SUMMARY: When formed in 1995, Laboratory Corporation of America faced a financially-hostile marketplace for lab testing services. However, strategic planning retreats in 1997 and 1999 were pivotal in redirecting this billion-dollar lab behemoth toward financial stability. During 2000,…
“February 26, 2001 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VIII No. 3 – February 26, 2001 Issue
Multiplex testing on a single specimen is getting ever closer to the clinical marketplace. On February 19, LINCO Research, Inc. and Luminex Corporation announced an agreement that calls for LINCO to develop, manufacture, and market multianalyte immunoassay kits using…
Two Labs Complete IPOs, AML May be Next in Line
By Robert Michel | From the Volume VIII No. 1 – January 15, 2001 Issue
CEO SUMMARY: During the year 2000, investors liked the performance of clinical labs. When stock market woes surfaced this fall, it was not enough to dampen investor interest in Dynacare and Specialty Laboratories. Both companies funded their initial public stock offering in a difficult ma…
Dynacare’s Business Plan Includes New Direction
By Robert Michel | From the Volume VIII No. 1 – January 15, 2001 Issue
CEO SUMMARY: Look for Dynacare, Inc. to undergo a significant transformation. Although it will not abandon its efforts to partner with hospital laboratories, Dynacare has made a renewed commitment to expand and market itself as a provider of esoteric and reference testing. These changes a…
DNA Diagnostics Market, Kaiser Permanente, TriPath Imaging, LifeScan
By Robert Michel | From the Volume VIII No. 1 – January 15, 2001 Issue
DNA DIAGNOSTICS MARKET GROWTH TO BE DOMINATED BY PCR TECHNOLOGY FOR THE YEAR 2000, total DNA diagnostic technology sales were estimated to be $517 million. By 2005, this number should increase to $771 million, a growth rate of 8.4% per year. This is the conclusion of Laura Roth, author of â…
Prognostic versus Diagnostic Lab Medicine
By R. Lewis Dark | From the Volume VII No. 16 – November 13, 2000 Issue
MOST OF YOU ARE FAMILIAR WITH THE RACE TO DEVELOP effective laboratory tests and pharmaceuticals based on rapidly-developing genetic and molecular knowledge. We all ask the same question: when will my laboratory have to buy this technology and offer these new tests? For most of us, the answer is “…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
Dr. Bruce Friedman Identifies Market Dynamics Driving Evolution of Lab Information Services
By Robert Michel | From the Volume VII No. 11 – July 31, 2000 Issue
CEO SUMMARY: Probably no one is better positioned to identify the evolution of laboratory information services than Bruce Friedman, M.D., Professor of Pathology at the University of Michigan Medical School in Ann Arbor. For almost 20 years, he has hosted the pre-eminent meeting in laborat…
“July 31, 2000 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume VII No. 11 – July 31, 2000 Issue
Medical Management Programs, Inc. (MMP) of Southfield, Michigan is the new owner of the TPA (third party administrator) business formerly held by Universal Standard Medical Laboratories. MMP purchased the TPA business involving lab testing and home health services from USML’s Chapt…
Luminex Raises $83 Mil In Public Stock Offering
By Robert Michel | From the Volume VII No. 7 – May 8, 2000 Issue
CEO SUMMARY: During the past year, Luminex Corporation moved swiftly to push its LabMAPâ„¢ multiplex testing technology into the bioassay marketplace. It found high interest among companies in the pharmaceutical, diagnostics, and bioresearch industries. Luminex executives say that a numbe…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized